We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00367445
Recruitment Status : Completed
First Posted : August 22, 2006
Last Update Posted : January 29, 2008
Information provided by:

August 21, 2006
August 22, 2006
January 29, 2008
September 2006
Not Provided
Variability of blood glucose over a period of 72 hours
Same as current
Complete list of historical versions of study NCT00367445 on ClinicalTrials.gov Archive Site
Insulin pharmacokinetics
Same as current
Not Provided
Not Provided
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
A 1 Month, Open-Label Inpatient, Randomized Cross-Over Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On 24-Hour Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Oral Agents
To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus
Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Drug: Inhaled Human Insulin (Exubera)
  • Drug: Insulin Glargine (Lantus)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
February 2007
Not Provided

Inclusion Criteria:

  • Diabetes mellitus Type 2

Exclusion Criteria:

  • Severe Asthma, severe COPD
  • Smoking
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP